» Articles » PMID: 18793400

Impact of Empiric Antimicrobial Therapy on Outcomes in Patients with Escherichia Coli and Klebsiella Pneumoniae Bacteremia: a Cohort Study

Overview
Journal BMC Infect Dis
Publisher Biomed Central
Date 2008 Sep 17
PMID 18793400
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

Background: It is unclear whether appropriate empiric antimicrobial therapy improves outcomes in patients with bacteremia due to Escherichia coli or Klebsiella. The objective of this study is to assess the impact of appropriate empiric antimicrobial therapy on in-hospital mortality and post-infection length of stay in patients with Escherichia coli or Klebsiella bacteremia while adjusting for important confounding variables.

Methods: We performed a retrospective cohort study of adult patients with a positive blood culture for E. coli or Klebsiella between January 1, 2001 and June 8, 2005 and compared in-hospital mortality and post-infection length of stay between subjects who received appropriate and inappropriate empiric antimicrobial therapy. Empiric therapy was defined as the receipt of an antimicrobial agent between 8 hours before and 24 hours after the index blood culture was drawn and was considered appropriate if it included antimicrobials to which the specific isolate displayed in vitro susceptibility. Data were collected electronically and through chart review. Survival analysis was used to statistically assess the association between empiric antimicrobial therapy and outcome (mortality or length of stay). Multivariable Cox proportional hazards models were used to calculate hazard ratios (HR) and 95% confidence intervals (CI).

Results: Among 416 episodes of bacteremia, 305 (73.3%) patients received appropriate empiric antimicrobial therapy. Seventy-one (17%) patients died before discharge from the hospital. The receipt of appropriate antimicrobial agents was more common in hospital survivors than in those who died (p = 0.04). After controlling for confounding variables, there was no association between the receipt of appropriate empiric antimicrobial therapy and in-hospital mortality (HR, 1.03; 95% CI, 0.60 to 1.78). The median post-infection length of stay was 7 days. The receipt of appropriate antimicrobial agents was not associated with shortened post-infection length of stay, even after controlling for confounding (HR, 1.11; 95% CI 0.86 to 1.44).

Conclusion: Appropriate empiric antimicrobial therapy for E. coli and Klebsiella bacteremia is not associated with lower in-hospital mortality or shortened post-infection length of stay. This suggests that the choice of empiric antimicrobial agents may not improve outcomes and also provides data to support a randomized trial to test the hypothesis that use (and overuse) of broad-spectrum antibiotics prior to the availability of culture results is not warranted.

Citing Articles

Impact of Gram-Negative Bacilli Resistance Rates on Risk of Death in Septic Shock and Pneumonia.

Hixon A, Micek S, Fraser V, Kollef M, Vazquez Guillamet M Open Forum Infect Dis. 2024; 11(5):ofae219.

PMID: 38770211 PMC: 11103621. DOI: 10.1093/ofid/ofae219.


Impact of a multidisciplinary management team on clinical outcome in ICU patients affected by Gram-negative bloodstream infections: a pre-post quasi-experimental study.

Rinaldi M, Gatti M, Tonetti T, Nocera D, Ambretti S, Berlingeri A Ann Intensive Care. 2024; 14(1):36.

PMID: 38448761 PMC: 10917714. DOI: 10.1186/s13613-024-01271-9.


A Review: Antimicrobial Therapy for Human Pythiosis.

Medhasi S, Chindamporn A, Worasilchai N Antibiotics (Basel). 2022; 11(4).

PMID: 35453202 PMC: 9029071. DOI: 10.3390/antibiotics11040450.


Risk factors for functional decline among survivors of Gram-negative bloodstream infection: A prospective cohort study.

Turjeman A, Koppel F, Franceschini E, Yahav D, Dolci G, Babich T PLoS One. 2021; 16(11):e0259707.

PMID: 34788325 PMC: 8598031. DOI: 10.1371/journal.pone.0259707.


Genome Sequence of Klebsiella pneumoniae YBQ, a Clinical Strain Isolated from the Sputum of a Patient with Severe Pneumonia.

Zou J, Chen Z, Zhang X, Yuan Y, Jing H, Zou Q Microbiol Resour Announc. 2020; 9(47).

PMID: 33214313 PMC: 7679106. DOI: 10.1128/MRA.01223-20.


References
1.
Du B, Long Y, Liu H, Chen D, Liu D, Xu Y . Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae bloodstream infection: risk factors and clinical outcome. Intensive Care Med. 2002; 28(12):1718-23. DOI: 10.1007/s00134-002-1521-1. View

2.
MacArthur R, Miller M, Albertson T, Panacek E, Johnson D, Teoh L . Adequacy of early empiric antibiotic treatment and survival in severe sepsis: experience from the MONARCS trial. Clin Infect Dis. 2003; 38(2):284-8. DOI: 10.1086/379825. View

3.
Hansen D, Gottschau A, Kolmos H . Epidemiology of Klebsiella bacteraemia: a case control study using Escherichia coli bacteraemia as control. J Hosp Infect. 1998; 38(2):119-32. DOI: 10.1016/s0195-6701(98)90065-2. View

4.
Zaragoza R, Artero A, Camarena J, Sancho S, Gonzalez R, Nogueira J . The influence of inadequate empirical antimicrobial treatment on patients with bloodstream infections in an intensive care unit. Clin Microbiol Infect. 2003; 9(5):412-8. DOI: 10.1046/j.1469-0691.2003.00656.x. View

5.
Knaus W, Wagner D, Draper E, Zimmerman J, Bergner M, Bastos P . The APACHE III prognostic system. Risk prediction of hospital mortality for critically ill hospitalized adults. Chest. 1991; 100(6):1619-36. DOI: 10.1378/chest.100.6.1619. View